
Bridget E. Bunner
Examiner (ID: 17180)
| Most Active Art Unit | 1647 |
| Art Unit(s) | 1647, 1644 |
| Total Applications | 1462 |
| Issued Applications | 724 |
| Pending Applications | 157 |
| Abandoned Applications | 602 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 11555221
[patent_doc_number] => 20170101466
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-04-13
[patent_title] => 'ANTI-BLYS ANTIBODIES'
[patent_app_type] => utility
[patent_app_number] => 15/315851
[patent_app_country] => US
[patent_app_date] => 2015-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 29295
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15315851
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/315851 | ANTI-BLYS ANTIBODIES | May 31, 2015 | Abandoned |
Array
(
[id] => 11956358
[patent_doc_number] => 20170260508
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-09-14
[patent_title] => 'LILRB2 AND NOTCH-MEDIATED EXPANSION OF HEMATOPOIETIC PRECURSOR CELLS'
[patent_app_type] => utility
[patent_app_number] => 15/313043
[patent_app_country] => US
[patent_app_date] => 2015-05-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 63
[patent_figures_cnt] => 63
[patent_no_of_words] => 30960
[patent_no_of_claims] => 208
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15313043
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/313043 | LILRB2 and notch-mediated expansion of hematopoietic precursor cells | May 20, 2015 | Issued |
Array
(
[id] => 12058643
[patent_doc_number] => 20170334988
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-11-23
[patent_title] => 'BAK BINDING PROTEINS'
[patent_app_type] => utility
[patent_app_number] => 15/313761
[patent_app_country] => US
[patent_app_date] => 2015-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 28072
[patent_no_of_claims] => 37
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15313761
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/313761 | Bak binding proteins | May 19, 2015 | Issued |
Array
(
[id] => 13635193
[patent_doc_number] => 09844546
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-12-19
[patent_title] => Antibody against human HIF hydroxylase
[patent_app_type] => utility
[patent_app_number] => 14/713085
[patent_app_country] => US
[patent_app_date] => 2015-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 28
[patent_no_of_words] => 53660
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14713085
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/713085 | Antibody against human HIF hydroxylase | May 14, 2015 | Issued |
Array
(
[id] => 11964921
[patent_doc_number] => 20170269075
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-09-21
[patent_title] => 'BIOMARKERS PREDICTIVE OF LUPUS PROGRESSION AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/310204
[patent_app_country] => US
[patent_app_date] => 2015-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 35269
[patent_no_of_claims] => 77
[patent_no_of_ind_claims] => 64
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15310204
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/310204 | BIOMARKERS PREDICTIVE OF LUPUS PROGRESSION AND USES THEREOF | May 10, 2015 | Abandoned |
Array
(
[id] => 12305946
[patent_doc_number] => 09938348
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-04-10
[patent_title] => Stimulation via TLR4/MD-2 to reverse type 1 diabetes
[patent_app_type] => utility
[patent_app_number] => 15/302772
[patent_app_country] => US
[patent_app_date] => 2015-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 23
[patent_no_of_words] => 5421
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15302772
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/302772 | Stimulation via TLR4/MD-2 to reverse type 1 diabetes | Apr 16, 2015 | Issued |
Array
(
[id] => 15011013
[patent_doc_number] => 10451636
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-10-22
[patent_title] => Protein biomarkers for immune assessment and prediction of transplant rejection
[patent_app_type] => utility
[patent_app_number] => 15/302463
[patent_app_country] => US
[patent_app_date] => 2015-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 13
[patent_no_of_words] => 15133
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15302463
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/302463 | Protein biomarkers for immune assessment and prediction of transplant rejection | Apr 8, 2015 | Issued |
Array
(
[id] => 11403038
[patent_doc_number] => 20170023576
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-01-26
[patent_title] => 'NOTCH3 ANTIBODIES AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/301161
[patent_app_country] => US
[patent_app_date] => 2015-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 24318
[patent_no_of_claims] => 47
[patent_no_of_ind_claims] => 31
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15301161
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/301161 | NOTCH3 ANTIBODIES AND USES THEREOF | Apr 2, 2015 | Abandoned |
Array
(
[id] => 10312576
[patent_doc_number] => 20150197578
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-07-16
[patent_title] => 'Anti-Tie2 Antibodies and Uses Thereof'
[patent_app_type] => utility
[patent_app_number] => 14/671494
[patent_app_country] => US
[patent_app_date] => 2015-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 15938
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14671494
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/671494 | Anti-Tie2 antibodies and uses thereof | Mar 26, 2015 | Issued |
Array
(
[id] => 11901988
[patent_doc_number] => 09771411
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-09-26
[patent_title] => 'Method of treating cancer by administering EGFR and EGFR/IGFIR binding molecules'
[patent_app_type] => utility
[patent_app_number] => 14/664290
[patent_app_country] => US
[patent_app_date] => 2015-03-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 57
[patent_figures_cnt] => 93
[patent_no_of_words] => 62412
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 129
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14664290
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/664290 | Method of treating cancer by administering EGFR and EGFR/IGFIR binding molecules | Mar 19, 2015 | Issued |
Array
(
[id] => 10367093
[patent_doc_number] => 20150252097
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-09-10
[patent_title] => 'TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KINASES RECEPTORS, INCLUDING IGF-IR'
[patent_app_type] => utility
[patent_app_number] => 14/659028
[patent_app_country] => US
[patent_app_date] => 2015-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 38
[patent_figures_cnt] => 38
[patent_no_of_words] => 47039
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14659028
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/659028 | TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KINASES RECEPTORS, INCLUDING IGF-IR | Mar 15, 2015 | Abandoned |
Array
(
[id] => 11618349
[patent_doc_number] => 20170128536
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-05-11
[patent_title] => 'NEW PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS'
[patent_app_type] => utility
[patent_app_number] => 15/118337
[patent_app_country] => US
[patent_app_date] => 2015-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 16999
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15118337
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/118337 | Pharmaceutical compositions and their use for the treatment of autoimmune disorders | Mar 12, 2015 | Issued |
Array
(
[id] => 11304810
[patent_doc_number] => 09512196
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-12-06
[patent_title] => 'Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling'
[patent_app_type] => utility
[patent_app_number] => 14/639782
[patent_app_country] => US
[patent_app_date] => 2015-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 43
[patent_no_of_words] => 22566
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14639782
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/639782 | Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling | Mar 4, 2015 | Issued |
Array
(
[id] => 11401751
[patent_doc_number] => 20170022289
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-01-26
[patent_title] => 'METHODS FOR TREATING CANCER WITH NOTCH1 ANTIBOIDES'
[patent_app_type] => utility
[patent_app_number] => 15/123864
[patent_app_country] => US
[patent_app_date] => 2015-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 29621
[patent_no_of_claims] => 68
[patent_no_of_ind_claims] => 54
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15123864
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/123864 | METHODS FOR TREATING CANCER WITH NOTCH1 ANTIBOIDES | Mar 3, 2015 | Abandoned |
Array
(
[id] => 14145493
[patent_doc_number] => 10253105
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-04-09
[patent_title] => Bispecific antibody binding to human TLR2 and human TLR4
[patent_app_type] => utility
[patent_app_number] => 15/121567
[patent_app_country] => US
[patent_app_date] => 2015-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 3
[patent_no_of_words] => 23123
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15121567
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/121567 | Bispecific antibody binding to human TLR2 and human TLR4 | Feb 26, 2015 | Issued |
Array
(
[id] => 12009714
[patent_doc_number] => 09803018
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-10-31
[patent_title] => 'Amino acid sequences directed against cellular receptors for viruses and bacteria'
[patent_app_type] => utility
[patent_app_number] => 14/627035
[patent_app_country] => US
[patent_app_date] => 2015-02-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 25
[patent_no_of_words] => 131609
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 218
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14627035
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/627035 | Amino acid sequences directed against cellular receptors for viruses and bacteria | Feb 19, 2015 | Issued |
Array
(
[id] => 10331791
[patent_doc_number] => 20150216795
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-08-06
[patent_title] => 'ARTICLE OF MANUFACTURE COMPRISING AFLIBERCEPT OR ZIV-AFLIBERCEPT'
[patent_app_type] => utility
[patent_app_number] => 14/611561
[patent_app_country] => US
[patent_app_date] => 2015-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 15293
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 9
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14611561
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/611561 | ARTICLE OF MANUFACTURE COMPRISING AFLIBERCEPT OR ZIV-AFLIBERCEPT | Feb 1, 2015 | Abandoned |
Array
(
[id] => 10333263
[patent_doc_number] => 20150218267
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-08-06
[patent_title] => 'NOVEL ANTI-BAFF ANTIBODIES'
[patent_app_type] => utility
[patent_app_number] => 14/609756
[patent_app_country] => US
[patent_app_date] => 2015-01-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 37623
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14609756
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/609756 | Anti-BAFF antibodies | Jan 29, 2015 | Issued |
Array
(
[id] => 10312561
[patent_doc_number] => 20150197563
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-07-16
[patent_title] => 'NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 14/600641
[patent_app_country] => US
[patent_app_date] => 2015-01-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 44
[patent_figures_cnt] => 44
[patent_no_of_words] => 54815
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14600641
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/600641 | Method of treating cancer by administering a monoclonal antibody that binds human NOTCH2 and NOTCH3 | Jan 19, 2015 | Issued |
Array
(
[id] => 14948431
[patent_doc_number] => 10435474
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-10-08
[patent_title] => Baff selective binding compounds and related methods
[patent_app_type] => utility
[patent_app_number] => 15/107921
[patent_app_country] => US
[patent_app_date] => 2014-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 19655
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15107921
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/107921 | Baff selective binding compounds and related methods | Dec 21, 2014 | Issued |